Brethine

Brethine

 [breth´ēn]
trademark for preparations sof terbutaline sulfate, a bronchodilator.

Brethine

a trademark for a beta2 receptor agonist agent (terbutaline sulfate).
References in periodicals archive ?
Terbutaline sulfate Bedford Laboratories Brethine injection
On day 3, labor was induced with oxytocin with brethine at the bedside for fetal heart rate decelerations.
Brethine is a medication commonly used for prevention and reversal of bronchospasm, but in obstetrics it helps to prevent premature labor.
Ditzian-Kadanoff et al (3) described a pregnant woman who had polymyositis with myoglobinuria after being on Brethine (0.
The company has also gained approval of medroxyprogesterone acetate injectable suspension, the generic equivalent of Pfizer's Depo-Provera, and of terbutaline sulfate injection, equivalent to AAI Pharmaceuticals' Brethine.
Brethine is marketed for the prevention and reversal of bronchospasm.
As the first generic version of Brethine this product will offer both patients and payers a cost-effective alternative to the brand.
Defendants emphasized increased revenues throughout the Class Period, fueled by strong sales of pharmaceutical products including sales of Brethine, an asthma medication.
On February 5, 2004, before the market opened, defendants shocked the market by announcing that due to excessive product returns of products such as Brethine, and necessary additions to product return reserves, fourth quarter net revenues were reduced by $15.
His omission prevented timely serial monitoring to determine if the contractions were causing the cervical change, and if the prescribed tocolytic, Brethine, was working or needed to be replaced.
Brethine, which is marketed by Novartis for the prevention and reversal of bronchospasm, had sales of approximately $15 million in the U.
Horizon Pharmaceutical Corporation, a privately held emerging pharmaceutical company, and Novartis Pharmaceuticals Corporation, a leader in Life Sciences, announced today a promotion agreement enabling Horizon to promote Novartis's Brethine (R), a prescription respiratory medicine for the treatment of asthma to physicians on behalf of Novartis.